These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15998966)

  • 21. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutated or non-mutated? Which database to choose when determining the IgVH hypermutation status in chronic lymphocytic leukemia?
    Peková S; Baran-Marszak F; Schwarz J; Matoska V
    Haematologica; 2006 Mar; 91(3):ELT01. PubMed ID: 16533734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
    Bomben R; Dal Bo M; Capello D; Forconi F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Zucchetto A; Bertoni F; Rossi FM; Bulian P; Cattarossi I; Ilariucci F; Sozzi E; Spina V; Zucca E; Degan M; Lauria F; Del Poeta G; Efremov DG; Marasca R; Gaidano G; Gattei V
    Br J Haematol; 2009 Feb; 144(4):492-506. PubMed ID: 19036101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic lymphocytic leukemia patients with a V1-69 gene rearrangement do not have inferior survival with respect to patients that express other unmutated V(H) genes.
    Panovska-Stavridis I; Ivanovski M; Siljanovski N; Cevreska L; Efremov DG
    Leuk Res; 2007 Feb; 31(2):245-8. PubMed ID: 16797703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns.
    Irons RD; Le A; Bao L; Zhu X; Ryder J; Wang XQ; Ji M; Chen Y; Wu X; Lin G
    Leuk Res; 2009 Dec; 33(12):1599-603. PubMed ID: 19428103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
    Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications.
    Hultdin M; Rosenquist R; Thunberg U; Tobin G; Norrback KF; Johnson A; Sundström C; Roos G
    Br J Cancer; 2003 Feb; 88(4):593-8. PubMed ID: 12592375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.
    Marasca R; Maffei R; Morselli M; Zucchini P; Castelli I; Martinelli S; Fontana M; Ravanetti S; Curotti M; Leonardi G; Cagossi K; Partesotti G; Torelli G
    J Mol Diagn; 2005 Nov; 7(5):566-74. PubMed ID: 16258154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
    Chen YH; Peterson LC; Dittmann D; Evens A; Rosen S; Khoong A; Shankey TV; Forman M; Gupta R; Goolsby CL
    Am J Clin Pathol; 2007 Feb; 127(2):182-91. PubMed ID: 17210531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
    Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
    Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.
    Tobin G; Rosenquist R
    Med Oncol; 2005; 22(3):217-28. PubMed ID: 16110132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chronic lymphoid leukemia: a single disease or 2 distinct diseases?].
    Dighiero G
    Bull Acad Natl Med; 2002; 186(7):1251-66; discussion 1266-8. PubMed ID: 12669665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia.
    Bagnara D; Callea V; Stelitano C; Morabito F; Fabris S; Neri A; Zanardi S; Ghiotto F; Ciccone E; Grossi CE; Fais F
    Br J Haematol; 2006 Apr; 133(1):50-8. PubMed ID: 16512828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.
    Kharfan-Dabaja MA; Chavez JC; Khorfan KA; Pinilla-Ibarz J
    Cancer; 2008 Sep; 113(5):897-906. PubMed ID: 18618518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.
    Dal-Bo M; Del Giudice I; Bomben R; Capello D; Bertoni F; Forconi F; Laurenti L; Rossi D; Zucchetto A; Pozzato G; Marasca R; Efremov DG; Guarini A; Del Poeta G; Foà R; Gaidano G; Gattei V
    Br J Haematol; 2011 Apr; 153(1):3-14. PubMed ID: 21303354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
    Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
    Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors.
    Belessi CJ; Davi FB; Stamatopoulos KE; Degano M; Andreou TM; Moreno C; Merle-Béral H; Crespo M; Laoutaris NP; Montserrat E; Caligaris-Cappio F; Anagnostopoulos AZ; Ghia P
    Eur J Immunol; 2006 Jul; 36(7):1963-74. PubMed ID: 16783849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.
    van't Veer MB; Brooijmans AM; Langerak AW; Verhaaf B; Goudswaard CS; Graveland WJ; van Lom K; Valk PJ
    Haematologica; 2006 Jan; 91(1):56-63. PubMed ID: 16434371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
    Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
    Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLL patients from a Northeastern region of Italy.
    Donisi PM; Di Lorenzo N; Riccardi M; Paparella A; Sarpellon C; Zupo S; Bertoldero G; Minotto C; Stracca-Pansa V
    Diagn Mol Pathol; 2006 Dec; 15(4):206-15. PubMed ID: 17122648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.